Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis - Wikidata - wikimedia - TriplyDB

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

http://www.wikidata.org/entity/Q30577042

about

Galeterone for the treatment of advanced prostate cancer: the evidence to date Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Abiraterone in the treatment of metastatic castration-resistant prostate cancer Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer Recent progress in pharmaceutical therapies for castration-resistant prostate cancer Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Bone-targeting agents in prostate cancer.Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer Practical guide to the use of abiraterone in castration resistant prostate cancer.CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Novel drugs targeting the androgen receptor pathway in prostate cancer.Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committ Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countries Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries.Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel.Validation and clinical utility of prostate cancer biomarkers.Metabolic and toxicological considerations of newly approved prostate cancer drugs.Recent advances revolutionize treatment of metastatic prostate cancer.Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer.Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.Novel bone-targeting agents in prostate cancer.Managing bone metastases and reducing skeletal related events in prostate cancer.Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice.

P2860

Q26739887-4EB46DD1-0E6C-47A2-8100-F2C9B37C9ADC Q26772883-5B7557F5-C504-44D1-84E7-2D627F14140E Q26852544-1DC32F99-D628-44CC-A310-42DB5C1921D5 Q26853635-F040D8DC-AD76-4209-B85A-FC5FC1FEC99B Q27002342-5820DBE9-0FE8-47AD-BFD5-3E6741DEF09D Q27022567-867A106D-23FF-4F39-B823-3BD14547EAB3 Q27022715-6B7169D5-D901-4E43-A74D-8F2BE4311073 Q30852837-2573C776-999D-43EC-BAE1-6F54332DA5AC Q33621403-C6262DC4-F852-47C5-978E-61A9CE724AE2 Q33864723-BEADD557-8147-4A2A-A400-8F2EC999A61C Q33924147-5FD11930-EE3E-4625-A844-75778AB60737 Q34023510-E8858B9A-5DAC-4CA9-9624-72602AE3F95F Q34070638-ACDCD0CF-C401-4E11-9762-0B3BB1CB217B Q34387852-4393B72B-87C3-4EC3-BA83-09CB5E1E7D68 Q34395777-51BC9E8C-E50C-48DE-8873-C970B56D891E Q34448130-40AF8FB6-A5F6-43AB-9598-CEF8CE517380 Q34655529-7B21A605-383B-46FF-9537-A470DD882C97 Q35087364-B7C8613B-2C46-4A4F-BA1F-FD1B83A403E3 Q35879087-F50A92AF-DB74-4815-B42D-6A45B80355F0 Q36335307-E29F1D79-9565-467A-B864-873ABDF15DBF Q36492222-F3D85795-F9B0-4B97-97E8-CF85A283C1B1 Q36507013-A51B7619-6D36-4369-BC96-4DF0CC67D3F1 Q37076775-60BA1F8D-4CB0-4EA9-80F0-9D084E3040B0 Q37126921-B489AC8B-24EF-4227-95FB-CD838FCA51F5 Q37166534-B26AF5ED-81A9-4A32-8913-5B52918CAC50 Q37240851-A6D3237D-EA19-4F4E-BE1C-C263F7913F96 Q37499980-1A19EA14-2404-4068-BF0B-D7226C3B71CB Q37620953-074FDF8E-C7AC-4350-95AC-6EFBA444064E Q37638333-7FE97269-7B4A-49CD-8418-696F6A445214 Q38086420-E6717210-48B8-423C-ADD7-FB9E033B1A35 Q38098596-6B439EBB-0B09-44C7-970F-D825C3830C8B Q38125501-CB1D8838-8EF8-4647-A624-BB543B3C386F Q38131735-3FDC8C21-5AAD-4F48-B094-0C406403BD6C Q38165773-EBD7260E-A61A-40B9-B7F9-BF1CC313DE18 Q38181005-5AE716D9-6A95-4930-888C-FF43517B34C7 Q38183819-E1253F16-406C-4706-BB69-BD82FFAD8A4B Q38198934-F58B71BE-CD4F-4BC0-A82E-8A9AA4DCFFE2 Q38211359-5A853731-32D0-40AB-A4A4-5B8B759965D5 Q38212470-8C9C2DD2-8EEC-446D-9554-287AF08A21A9 Q38240768-E0E9B6EC-95FF-42DE-A78B-8E11FF21F922

P2860

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

http://www.wikidata.org/entity/Q30577042

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Effect of abiraterone acetate ...... a from the COU-AA-301 randomis

@ast

Effect of abiraterone acetate ...... a from the COU-AA-301 randomis

@en

type

label

Effect of abiraterone acetate ...... a from the COU-AA-301 randomis

@ast

Effect of abiraterone acetate ...... a from the COU-AA-301 randomis

@en

prefLabel

Effect of abiraterone acetate ...... a from the COU-AA-301 randomis

@ast

Effect of abiraterone acetate ...... a from the COU-AA-301 randomis

@en

P1433

Q30577042-D3E9449B-9633-4600-82B5-3FB885D63DA5

P1476

Q30577042-91B98A04-BAC0-4923-BC66-880183F7609F

P2093

Q30577042-041B1CA5-DE72-4C42-AEA5-F264EAC71613

Q30577042-06CEC1FD-C259-46A1-A693-A24D1C911BC2

Q30577042-1391A64C-132F-4BF2-B1A8-92F7BEC7CC56

Q30577042-29DAE182-EF7E-4709-9406-6E60856B2B6A

Q30577042-352737F4-736E-4B04-8F03-1BAE1306B2F8

Q30577042-4BD09A22-CACF-45DE-9759-D69F857F5EDA

Q30577042-4FDB16FE-D2BD-453C-9EB8-C2B1DB5AA0BD

Q30577042-588CB536-022C-4583-BE6E-412772E61CE9

Q30577042-88376874-D0ED-4D60-8D99-2D5F927A3D4E

Q30577042-8F66A341-9F07-4E55-A47C-44CCF5151C22

P304

Q30577042-3DBD6735-7BFB-479C-931E-9D59A1FE9308

P31

Q30577042-AF7629E4-DC45-484D-AA54-FE175FE3186B

P356

Q30577042-E23E5EEB-ED20-420F-8DC5-8941BCF4844F

P433

Q30577042-237BBF2F-EE5D-4869-9D06-031047A60E76

P478

Q30577042-E369AED0-1349-4FD2-AD2C-3A5AABA76E64

P50

Q30577042-641E4AF3-3870-4C14-814B-34A1159AAAE4

Q30577042-FC02A137-2FD7-400B-85BD-30F23CF3EB1B

P577

Q30577042-396FC2C2-A031-4D9C-AB72-69430FB7FFB1

P698

Q30577042-5D6FA02B-0754-4DC6-B1D0-BEFEEC1D6589

P921

Q30577042-51F4D46C-B514-47BF-A7AD-6FDC45964C4F

Q30577042-C22279FB-6FE7-4340-9F74-E8C7C2B8F970

P356

S1470-2045(12)70473-4

P1433

The Lancet Oncology

P1476

Effect of abiraterone acetate ...... a from the COU-AA-301 randomis

@en

P2093

Arturo Molina

http://www.w3.org/2001/XMLSchema#string

Cameron S Liu

http://www.w3.org/2001/XMLSchema#string

Christopher J Logothetis

http://www.w3.org/2001/XMLSchema#string

Christopher M Haqq

http://www.w3.org/2001/XMLSchema#string

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

Dennis D Gagnon

http://www.w3.org/2001/XMLSchema#string

Eleni Efstathiou

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

Kim N Chi

http://www.w3.org/2001/XMLSchema#string

P304

1210-1217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(12)70473-4

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23142059

http://www.w3.org/2001/XMLSchema#string

P921